NO20071866L - Prosesser for beskyttelse av optisk aktive aminderivater - Google Patents

Prosesser for beskyttelse av optisk aktive aminderivater

Info

Publication number
NO20071866L
NO20071866L NO20071866A NO20071866A NO20071866L NO 20071866 L NO20071866 L NO 20071866L NO 20071866 A NO20071866 A NO 20071866A NO 20071866 A NO20071866 A NO 20071866A NO 20071866 L NO20071866 L NO 20071866L
Authority
NO
Norway
Prior art keywords
optically active
amine derivatives
active amine
processes
protecting
Prior art date
Application number
NO20071866A
Other languages
English (en)
Inventor
Shinichi Urayama
Eigo Mutou
Atsushi Inagaki
Takashi Okada
Osamu Sugisaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36059992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071866(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20071866L publication Critical patent/NO20071866L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

Det beskrives en industriell prosess for fremstilling av optisk aktive aminderivater i høyt utbytte under samtidig inbibering av dannelsen av biproduktet. Prosessen omfatter å underkaste (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yliden)etylamin en asymmetrisk reduksjon, katalytisk å redusere det oppnådde produkt ved en reaksjonstemperatur fra 40 til 100 oC og en pH på fra 3 til 9, og underkaste det oppnådde (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)etylamin en propionylering og så å krystallisere reaksjonsblandingen.
NO20071866A 2004-09-13 2007-04-12 Prosesser for beskyttelse av optisk aktive aminderivater NO20071866L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004265307 2004-09-13
PCT/JP2005/016761 WO2006030739A1 (ja) 2004-09-13 2005-09-12 光学活性アミン誘導体の製造方法

Publications (1)

Publication Number Publication Date
NO20071866L true NO20071866L (no) 2007-05-29

Family

ID=36059992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071866A NO20071866L (no) 2004-09-13 2007-04-12 Prosesser for beskyttelse av optisk aktive aminderivater

Country Status (31)

Country Link
US (4) US8097737B2 (no)
EP (2) EP2537842A1 (no)
JP (2) JP5127228B2 (no)
KR (1) KR101298335B1 (no)
CN (2) CN102516211A (no)
AR (1) AR050737A1 (no)
AU (1) AU2005283521B2 (no)
BR (1) BRPI0515170A (no)
CA (2) CA2764314C (no)
CR (2) CR8975A (no)
EC (1) ECSP077317A (no)
ES (1) ES2485890T3 (no)
GE (1) GEP20094725B (no)
GT (2) GT200500257A (no)
HN (1) HN2005000548A (no)
IL (2) IL181462A (no)
MA (1) MA28855B1 (no)
MX (1) MX2007002822A (no)
MY (2) MY147822A (no)
NO (1) NO20071866L (no)
NZ (1) NZ553562A (no)
PA (1) PA8645701A1 (no)
PE (3) PE20081390A1 (no)
RU (1) RU2385318C2 (no)
SA (1) SA05260347A (no)
SG (1) SG151330A1 (no)
TW (1) TWI400220B (no)
UA (1) UA95598C2 (no)
UY (1) UY29118A1 (no)
WO (1) WO2006030739A1 (no)
ZA (1) ZA200701724B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008123067A1 (ja) * 2007-03-19 2008-10-16 Takeda Pharmaceutical Company Limited アリルアミン不斉水素化法
WO2008150953A1 (en) * 2007-05-30 2008-12-11 Dr. Reddy's Laboratories Ltd. Process of making ramelteon and related substances
EP2069320A2 (en) 2007-05-31 2009-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US20090105490A1 (en) * 2007-07-12 2009-04-23 Nurit Perlman Polymorphic forms of ramelteon and processes for preparation thereof
CN101531647B (zh) * 2008-03-13 2012-10-31 常州亚邦制药有限公司 (±)-2-(1,6,7,8-四氢-2H-茚并[5,4-b]呋喃-8-基)乙胺的拆分方法
EP2328882A1 (en) * 2008-07-14 2011-06-08 LEK Pharmaceuticals d.d. Synthesis of 6,7-dihydro-1h-indeno[5,4-b]furan-8(2h)-one as intermediate in the preparation of ramelteon
WO2010045565A1 (en) * 2008-10-16 2010-04-22 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2010092107A1 (en) 2009-02-12 2010-08-19 Lek Pharmaceuticals D.D. Synthesis of (s)-n-[2-(1,6,7,8-tetrahydro-2h-indeno-[5,4-b]furan-8-yl)ethyl]propionamide
CN101824012B (zh) * 2009-03-02 2011-12-07 四川大学 2-(1,6,7,8-四氢-2H-茚并-[5,4-b]呋喃-8-基)乙腈及其制备方法和用途
WO2010103553A1 (en) 2009-03-10 2010-09-16 Industriale Chimica S.R.L. Process for the preparation of ramelteon
EP2243775A1 (en) 2009-04-07 2010-10-27 LEK Pharmaceuticals d.d. Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon
WO2011027323A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of ramelteon
WO2011027319A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Process for the preparation of an intermediate for ramelteon
CN101648931B (zh) * 2009-09-21 2012-05-09 四川大学 一种3-(2,3-二氢苯并呋喃-5-基)-丙酸的制备方法
CN101665477B (zh) * 2009-09-21 2012-05-09 四川大学 (e)-3-(苯并呋喃-5-基)丙烯酸酯类化合物、其制备方法和用途
EP2483258A1 (en) 2009-09-29 2012-08-08 Lonza Ltd. Process for preparing 1,2,6,7-tetrahydro-8h-indeno[5,4-b]furan-8-one
WO2012035303A2 (en) 2010-09-17 2012-03-22 Cipla Limited Et Al A novel process for synthesis of ramelteon, and key intermediates for the synthesis of ramelteon
CN103664849B (zh) * 2012-08-31 2017-03-29 上海阳帆医药科技有限公司 制备2‑(1,6,7,8‑四氢‑2H‑茚并[5,4‑b]呋喃‑8‑亚基乙胺的方法
CN102924410A (zh) * 2012-10-29 2013-02-13 华润赛科药业有限责任公司 一种雷美替胺的制备方法及其中间体
CN103396387A (zh) * 2013-08-07 2013-11-20 安徽联创药物化学有限公司 雷美替胺中间体的制备方法
CN105277628B (zh) * 2014-07-07 2017-05-31 南京长澳医药科技有限公司 通过高效液相色谱法分离测定雷美替胺及其杂质的方法
CN104402848B (zh) * 2014-09-22 2017-02-08 珠海联邦制药股份有限公司 雷美替胺中的杂质化合物的制备方法及制备的标准品
CN105622557B (zh) * 2014-11-05 2018-12-04 上海医药工业研究院 雷美替胺中间体及其制备方法
KR102359229B1 (ko) 2020-04-16 2022-02-07 제이투에이치바이오텍 (주) 라멜테온의 제조 방법 및 이러한 제조 방법에 이용되는 중간체 화합물
CN115477628A (zh) * 2022-10-17 2022-12-16 江苏海悦康医药科技有限公司 一种雷美替胺二聚体的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0757758B2 (ja) 1988-10-24 1995-06-21 高砂香料工業株式会社 ルテニウム―ホスフィン錯体
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
HU223094B1 (hu) 1995-03-02 2004-03-29 Sankyo Co., Ltd. Optikailag aktív tiazolidinonszármazékok, előállításuk, a vegyületeket hatóanyagként tartalmazó gyógyászati készítmények és tia-vagy oxazolidinonszármazékok alkalmazása gyógyászati készítmények előállítására
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
EP1199304A1 (en) * 1997-03-05 2002-04-24 Takeda Chemical Industries, Ltd. Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders
JP2884153B2 (ja) 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
JP4242940B2 (ja) 1997-02-13 2009-03-25 高砂香料工業株式会社 光学活性アミン誘導体の製造法
JP4081161B2 (ja) * 1997-09-05 2008-04-23 武田薬品工業株式会社 光学活性化合物の製造法
CN1206996C (zh) * 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
JP3633895B2 (ja) 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
DE60142305D1 (de) * 2000-11-17 2010-07-15 Takeda Pharmaceutical Pharmazeutische zubereitung enthaltend n-ä2-(1,6,7,8-tetrahydro-2h-indenoä5,4 büfuran-8-yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung

Also Published As

Publication number Publication date
GEP20094725B (en) 2009-07-10
CA2764314C (en) 2014-06-17
CA2764314A1 (en) 2006-03-23
UA95598C2 (ru) 2011-08-25
GT200500257AA (es) 2008-07-28
EP2537842A1 (en) 2012-12-26
ZA200701724B (en) 2008-08-27
EP1792899A1 (en) 2007-06-06
PE20130154A1 (es) 2013-02-27
AU2005283521B2 (en) 2011-10-13
JP2012116848A (ja) 2012-06-21
AR050737A1 (es) 2006-11-15
CA2579121C (en) 2013-07-30
CR20110698A (es) 2012-03-08
BRPI0515170A (pt) 2008-07-08
IL181462A (en) 2011-12-29
MY147822A (en) 2013-01-31
MX2007002822A (es) 2007-04-23
JPWO2006030739A1 (ja) 2008-05-15
SA05260347A (ar) 2005-12-03
US8097737B2 (en) 2012-01-17
RU2385318C2 (ru) 2010-03-27
PA8645701A1 (es) 2006-09-22
CA2579121A1 (en) 2006-03-23
US20140066499A1 (en) 2014-03-06
CR8975A (es) 2007-08-28
JP5615304B2 (ja) 2014-10-29
PE20060662A1 (es) 2006-08-22
US20090036521A1 (en) 2009-02-05
WO2006030739A1 (ja) 2006-03-23
US20120088826A1 (en) 2012-04-12
US20130079397A1 (en) 2013-03-28
MY158073A (en) 2016-08-30
ECSP077317A (es) 2007-04-26
UY29118A1 (es) 2006-06-30
AU2005283521A1 (en) 2006-03-23
JP5127228B2 (ja) 2013-01-23
CN101056867A (zh) 2007-10-17
IL181462A0 (en) 2007-07-04
US8609871B2 (en) 2013-12-17
TWI400220B (zh) 2013-07-01
KR20070054200A (ko) 2007-05-28
KR101298335B1 (ko) 2013-08-20
TW200613239A (en) 2006-05-01
SG151330A1 (en) 2009-04-30
MA28855B1 (fr) 2007-09-03
PE20081390A1 (es) 2008-10-24
CN102516211A (zh) 2012-06-27
EP1792899B1 (en) 2014-07-09
EP1792899A4 (en) 2009-12-16
GT200500257A (es) 2006-04-17
NZ553562A (en) 2010-08-27
ES2485890T3 (es) 2014-08-14
CN101056867B (zh) 2011-12-07
HN2005000548A (es) 2007-04-20
IL207510A (en) 2013-02-28
RU2007113811A (ru) 2008-10-20

Similar Documents

Publication Publication Date Title
NO20071866L (no) Prosesser for beskyttelse av optisk aktive aminderivater
CN105884781B (zh) 一种枸橼酸托法替布的制备方法
NO20072872L (no) Kjemisk prosess
NO20065191L (no) Fremgangsmate for fremstilling av dipeptidyl IV inhibitorer og mellomprodukter derav
Lin et al. A mild new procedure for production, cyclization and trapping of amidyl radicals: application to a formal total synthesis of peduncularine
Ohnishi et al. Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor
BR0214461A (pt) Processo para quaternização contìnua de aminas terciárias com halogeneto de alquila
WO2009052152A3 (en) Tigecycline and methods of preparing intermediates
WO2009124906A3 (en) A polymorph of argatroban monohydrate and a process for its synthesis
NO20082005L (no) Syntese av renininhibitorer omfattende en cyklotilfoyelsesreaksjon
WO2007018807A3 (en) Methods and intermediates for the synthesis of porphyrins
EP1460065A4 (en) METHOD FOR THE PRODUCTION OF CYCLIC DIAMINO COMPOUNDS BZW. THE SALTS
AU2007224066A1 (en) Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
CA2471730A1 (en) Process for preparing and purifying 1,7'-dimethyl-2'-propyl-2,5'-bi-1h-benzimidazole
NZ544004A (en) Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof
ATE321039T1 (de) Verfahren zur herstellung von losartan und losartan-kaliumsalz
ATE509117T1 (de) Herstellungsverfahren für hyaluronsäure oder ihre derivate
WO2012165023A1 (ja) 光学活性α－置換プロリン類の製造方法
KR102295388B1 (ko) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
ATE329900T1 (de) Verfahren zur herstellung von 2-pyrrolidon
Pesenti et al. Stereocontrolled synthesis of hydroxyethylamine isosteres via chiral sulfoxide chemistry
HUP0400606A2 (hu) 2-Metil-indol-4-ecetsav és intermedierei és eljárás előállításukra
HUP0401401A2 (hu) Eljárás 7-kinolinil-3,5-dihidroxi-hept-6-enoát előállítására
TW200740730A (en) Process for producing ethylenedlamine derivatives having halogenated-carbamate group and acyl group, and intermediates thereof
CN106478486B (zh) 一种β-羟基-α-氨基酸酯衍生物及其合成方法和应用

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application